TROPHY-U-01: Initial findings
Scott Tagawa, MD, MS, Weill Cornell Medicine, New York, NY, discusses the initial results from the TROPHY-U-01 phase II trial,…
Scott Tagawa, MD, MS, Weill Cornell Medicine, New York, NY, discusses the initial results from the TROPHY-U-01 phase II trial,…
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the…
Traditional tumor response assessments rely on radiographic scans after two months, often exposing patients to unnecessary toxicity before determining efficacy. Sakti Chakrabarti, MD, University Hospitals…
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the…
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the…
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the…
Aasma Shaukat, MD, MPH, NYU Grossman School of Medicine, New York, NY, comments on the potential of blood-based tests for colorectal cancer screening, highlighting their…
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the…
Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, highlights the importance of biomarkers in selecting patients for dual trastuzumab and pembrolizumab therapy…
Alexander Spira, MD, PhD, Virginia Cancer Specialist, Fairfax, VA, comments on the complexity of the post-osimertinib space in non-small cell lung cancer (NSCLC), noting the…
Hisato Kawakami, MD, PhD, Tohoku University, Sendai, Japan, discusses balancing efficacy and safety with the use of trastuzumab deruxtecan in patients with HER2+ gastric cancer,…